3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer - Preliminary results

Martin, T; Hey-Koch, S; Strassmann, G; Kolotas, C; Baltas, D; Rogge, B; Roddiger, S; Vogt, HG; Heyd, R; Dannenberg, T; Kurek, R; Tunn, U; Zamboglou, N

dc.contributor.author	Martin, T	en
dc.contributor.author	Hey-Koch, S	en
dc.contributor.author	Strassmann, G	en
dc.contributor.author	Kolotas, C	en
dc.contributor.author	Baltas, D	en
dc.contributor.author	Rogge, B	en
dc.contributor.author	Roddiger, S	en
dc.contributor.author	Vogt, HG	en
dc.contributor.author	Heyd, R	en
dc.contributor.author	Dannenberg, T	en
dc.contributor.author	Kurek, R	en
dc.contributor.author	Tunn, U	en
dc.contributor.author	Zamboglou, N	en
dc.date.accessioned	2014-03-01T01:49:41Z
dc.date.available	2014-03-01T01:49:41Z
dc.date.issued	2000	en
dc.identifier.issn	0179-7158	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/25888
dc.subject	prostate cancer	en
dc.subject	HDR brachytherapy	en
dc.subject	3D external beam radiotherapy	en
dc.subject	androgen deprivation	en
dc.subject	dose-volume histograms	en
dc.subject.classification	Oncology	en
dc.subject.classification	Radiology, Nuclear Medicine & Medical Imaging	en
dc.subject.other	LOCALIZED CARCINOMA	en
dc.subject.other	FOLLOW-UP	en
dc.subject.other	IRRADIATION	en
dc.subject.other	ADENOCARCINOMA	en
dc.subject.other	COMBINATION	en
dc.subject.other	RADIATION	en
dc.subject.other	THERAPY	en
dc.title	3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer - Preliminary results	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2000	en
heal.abstract	Background: Evaluation of feasibility, tolerance and efficiency for a new 3D interstitial HDR brachytherapy technique combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Patients and Methods: Between January 1997 and August 1998 we treated 35 patients with Stage cT1-3 N0 M0 prostate cancer. Thirty-two patients with a follow-up of 12 to 28 months (median: 18 months) were evaluated. After ultrasound-guided transrectal implantation of 4 non-parallel needles, CT based 3D brachytherapy treatment planning ("Offenbach system") was performed. All patients received 4 fractions brachytherapy using a fractional dose of 5 or 7 Gy, Time between each fraction was 14 days. After brachytherapy 3D external irradiation followed up to 39.6 or 45.0 Gy. All patients received androgen deprivation, starting 2 to 19 months before brachytherapy, ending 3 months after 3D external radiotherapy. Results: Posttreatment PSA levels dropped to <1.5 ng/ml in 29/32 patients (91%). In 25 patients PSA levels were <0.5 ng/ml, in 4 patients 0.5 to 1.5 ng/ml. In 2 patients we noted biochemical relapse. Transrectal implantation was very well tolerated. Grade 3 acute urinary toxicity occurred in 1 patient. We noted no Grade 2 or higher acute gastrointestinal toxicity. One patient developed a Grade 3 late urinary toxicity. No patient showed late gastrointestinal side effects. All 140 dose-volume histograms for 3D HDR brachytherapy were analyzed. Conclusions: The new 3D HDR brachytherapy technique, combined with 3D external irradiation and androgen deprivation, is a feasible, so far well tolerated and effective treatment in the short-time follow-up of median 18 months.	en
heal.publisher	URBAN & VOGEL	en
heal.journalName	STRAHLENTHERAPIE UND ONKOLOGIE	en
dc.identifier.isi	ISI:000088610200005	en
dc.identifier.volume	176	en
dc.identifier.issue	8	en
dc.identifier.spage	361	en
dc.identifier.epage	367	en